Edwards Lifesciences Reports Strong Q2 2026 Results With 13.6% Sales Growth, Raises Full-Year Guidance

Edwards Lifesciences Q2 2026 Earnings: Robust Growth, Upbeat Guidance, Clinical, and Regulatory Catalysts

Summary of Key Financial Results

Q2 2026 sales grew 13.6% to \$1.74 billion (12.5% in constant currency), exceeding prior expectations.
Transcatheter Aortic Valve Replacement (TAVR) sales rose 11.3% to \$1.26 billion (10.5% constant currency) amid strong global clinical momentum.
Transcatheter Mitral and Tricuspid Therapies (TMTT) sales surged 47.3% to \$195.9 million (44.8% constant currency), underscoring successful portfolio execution.
Q2 EPS was \$0.42 (GAAP); adjusted EPS was \$0.78, benefiting from strong revenue and phasing of strategic investments.
Gross profit margin was 77.5% (77.6% adjusted), in line with prior year, despite foreign exchange headwinds.
Operating profit margin reached 29.5% (30.0% adjusted), with 150 bps constant currency expansion expected for the full year.
Cash and cash equivalents stood at \$2.9 billion as of June 30, 2026, with \$600 million in total debt.

Upward Revised 2026 Guidance

Total company constant currency sales growth now guided to 10%-11% (from 9%-11%).
TAVR constant currency sales growth raised to 8%-9% (from 7%-9%).
TMTT sales guidance increased to \$760-\$780 million (from \$740-\$780 million).
Full-year total company sales expected in the range of \$6.6-\$6.9 billion.
Adjusted EPS guidance reaffirmed at \$2.95-\$3.05, representing 17% growth at the midpoint, despite a higher effective tax rate assumption (now at the high end of 16%-19%).

For Q3 2026, Edwards projects sales of \$1.63-\$1.71 billion and adjusted EPS of \$0.71-\$0.77.

Strategic Business and Clinical Highlights

TAVR – Strong Growth, Clinical Validation, and Regulatory Tailwinds

Global TAVR growth was supported by clinical data favoring early intervention for severe aortic stenosis (AS) and the durable performance of the SAPIEN platform.
Edwards benefitted from a competitor’s market exit in Q2 2025 and stability in average selling prices worldwide.
New 7-year PARTNER 3 trial data reinforced SAPIEN’s best-in-class durability, while a 5-year EARLY TAVR trial analysis added evidence for earlier AS intervention.
Upcoming presentation of PROGRESS trial results at TCT is expected to offer further insights into moderate AS management.
In the US, SAPIEN 3 Ultra RESILIA adoption drove market share gains. Medicare (CMS) is moving toward a revised National Coverage Determination (NCD) for TAVR, with a decision expected in September—this could further accelerate TAVR utilization among Medicare beneficiaries.
In Europe and Japan, updated guidelines and continued adoption of SAPIEN 3 Ultra RESILIA are strengthening Edwards’ competitive positioning.

TMTT – Explosive Growth and Pipeline Progress

TMTT sales rose sharply, driven by the differentiated PASCAL system and growing demand for mitral and tricuspid solutions.
Double-digit global procedural growth; strong physician enthusiasm for PASCAL due to its design and outcomes.
Fourth quarter catalysts include expected US and EU approvals of next-generation PASCAL with Capture Clarity technology and US approval for PASCAL in tricuspid disease.
EVOQUE tricuspid valve system is scaling in the US and Europe, with expanding access and ongoing adoption.
SAPIEN M3 mitral replacement system is in measured launch, supporting patients unsuitable for TEER, with strong early outcomes.

Surgical – Stable Growth and New Launches

Surgical group sales rose 6.5% (5.0% constant currency) to \$284 million, led by RESILIA tissue heart valves (INSPIRIS, MITRIS, KONECT).
10-year COMMENCE trial data showed favorable durability and low reoperation rates for RESILIA valves, even in younger patients.
Edwards received US approval for the ECLIPTIS left atrial appendage system, with a measured rollout planned for later this year.

Operational and Financial Details

SG&A expenses were \$561 million (32.2% of sales), down slightly as a percentage of sales, reflecting continued investment in commercial and patient support.
R&D expenses were \$279 million (16.0% of sales), down from 18.0% a year ago, but total spend increased, reflecting strategic prioritization of innovation.
Full-year R&D spend expected to be ~17% of sales in 2026.
Gross margin expected at the lower end of 78%-79% guidance, impacted by FX through hedging.
Operating profit margin expected at the high end of 28%-29% guidance, with 150 bps expansion expected for 2026.
Effective tax rate for 2026 (excluding special items) now expected at the high end of 16%-19%, reflecting recent California law limiting R&D credits and assumptions around global tax changes.
\$1.5 billion remains on share repurchase authorization.

Upcoming Catalysts and Events

Key clinical trial results (PROGRESS, CLASP IITR) to be presented at TCT later in 2026.
Potential Q4 US and EU approvals for next-generation PASCAL systems.
CMS’s anticipated final NCD update on TAVR in September, which could meaningfully expand access and reimbursement.
Ongoing launches and adoption of SAPIEN M3 and ECLIPTIS products.

Risks and Disclaimers for Investors

Forward-looking statements are subject to risks including clinical, regulatory, competitive, and reimbursement uncertainties, as well as currency and tax impacts.
See the company’s SEC filings for a detailed list of risks, including failure to innovate, manufacturing or quality issues, changes in healthcare legislation, and potential tax or IP challenges.

Conclusion and Impact for Shareholders

Edwards Lifesciences delivered a strong Q2 2026 performance, beating expectations and issuing positive upward revisions to its sales and TAVR/TMTT guidance. The company’s diversified product portfolio, robust pipeline, and multiple near-term regulatory and clinical catalysts position it for continued durable growth. Potentially price-sensitive events in the near term include the CMS NCD update for TAVR, key clinical trial data releases, and anticipated product approvals, all of which could further boost market adoption and revenue trajectory. Investors should also monitor the evolving tax landscape and foreign exchange headwinds, as these may impact margins and earnings.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Investors should review Edwards Lifesciences’ official filings and consult their financial advisor before making investment decisions.